Literature DB >> 21849188

Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma.

T V Johnson1, S Ali, A Abbasi, O Kucuk, W B Harris, K Ogan, J Pattaras, P T Nieh, F F Marshall, A O Osunkoya, V A Master.   

Abstract

PURPOSE: Serum C-reactive protein has been shown to have prognostic value in localized and metastatic renal cell carcinoma. However, the prognostic value of intratumor C-reactive protein remains unknown.
MATERIALS AND METHODS: A total of 95 patients with resected, clinically localized (T1-T4N0M0) clear cell renal cell carcinoma were followed postoperatively. Intratumor C-reactive protein expression was assessed in surgical specimens using immunohistochemical analysis. Patients were categorized by staining intensity into low risk (staining 0 to 1), intermediate risk (staining 2) and high risk (staining 3) groups. Kaplan-Meier and multivariate Cox regression analyses were used to examine overall survival across patient and disease characteristics. Variables examined in multivariate Cox regression analysis included T stage, Fuhrman nuclear grade, tumor size, preoperative serum C-reactive protein and intratumor C-reactive protein staining.
RESULTS: Followup extended up to 46 months with a mean (SD) of 29.8 (11.0) months. Twelve patients (12.6%) died during followup. Of all tumors 49.5%, 25.3% and 25.3% were graded by intratumor C-reactive protein staining as low risk (0 to 1), intermediate risk (2) and high risk (3), respectively. After controlling for variables significant on univariate analysis, patients in the high risk (3) group experienced a 27-fold increased risk of overall mortality compared to those in the low risk (0-1) group (HR 27.767, 95% CI 1.488-518.182). After adjusting for tumor staining, preoperative serum C-reactive protein was not a significant predictor of overall survival (p = 0.741).
CONCLUSIONS: Intratumor C-reactive protein may be a robust biomarker of prognosis in patients with localized renal cell carcinoma.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849188     DOI: 10.1016/j.juro.2011.06.014

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Do preoperative serum C-reactive protein levels predict the definitive pathological stage in patients with clinically localized prostate cancer?

Authors:  Thomas J Schnoeller; Julie Steinestel; Konrad Steinestel; Florian Jentzmik; Andres J Schrader
Journal:  Int Urol Nephrol       Date:  2015-03-19       Impact factor: 2.370

Review 2.  C-reactive protein as a biomarker for urological cancers.

Authors:  Kazutaka Saito; Kazunori Kihara
Journal:  Nat Rev Urol       Date:  2011-10-25       Impact factor: 14.432

3.  Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression.

Authors:  E Jason Abel; Tyler M Bauman; Madelyn Weiker; Fangfang Shi; Tracy M Downs; David F Jarrard; Wei Huang
Journal:  Hum Pathol       Date:  2014-01-28       Impact factor: 3.466

Review 4.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

5.  C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab.

Authors:  Ahmad Y Abuhelwa; Joaquim Bellmunt; Ganessan Kichenadasse; Ross A McKinnon; Andrew Rowland; Michael J Sorich; Ashley M Hopkins
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

6.  Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis.

Authors:  Liang Zhou; Xiang Cai; Qiang Liu; Zhong-Yu Jian; Hong Li; Kun-Jie Wang
Journal:  Sci Rep       Date:  2015-08-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.